Drug Profile
Research programme: bispecific antibody therapeutics - Merus/Ono Pharmaceutical
Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Merus; Ono Pharmaceutical
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in Japan
- 28 May 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in Netherlands
- 14 Mar 2018 Ono Pharmaceutical exercises its option to enter into a research and license agreement utilising Merus’ proprietary Biclonics®technology platform to generate a bispecific antibody for treatment of Autoimmune disorders